Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBITDA (2016 - 2026)

Aytu Biopharma has reported EBITDA over the past 15 years, most recently at -$2.0 million for Q4 2025.

  • Quarterly EBITDA fell 16.22% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.7 million through Dec 2025, down 33.58% year-over-year, with the annual reading at -$7.8 million for FY2025, 391.95% down from the prior year.
  • EBITDA was -$2.0 million for Q4 2025 at Aytu Biopharma, down from -$1.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $13.7 million in Q2 2023 and troughed at -$53.4 million in Q1 2022.
  • The 5-year median for EBITDA is -$2.0 million (2025), against an average of -$7.9 million.
  • Year-over-year, EBITDA crashed 678.72% in 2021 and then soared 251.6% in 2025.
  • A 5-year view of EBITDA shows it stood at -$11.3 million in 2021, then soared by 39.19% to -$6.9 million in 2022, then skyrocketed by 145.81% to $3.1 million in 2023, then plummeted by 153.88% to -$1.7 million in 2024, then decreased by 16.22% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBITDA are -$2.0 million (Q4 2025), -$1.5 million (Q3 2025), and -$7.6 million (Q2 2025).